Monday, December 16, 2024(Washington, DC) – Today, Mayor Muriel Bowser launched the DC Venture Capital Program, a new $26 million fund designed to make equity investments for early-stage, DC-based tech companies, prioritizing underrepresented founders.
“Washington, DC is the best place in the nation to launch and grow a business. We know, however, that sometimes talent alone isn’t enough to succeed – and that is why the city has stepped in with a suite of innovative grants to help more entrepreneurs get their fair shot,” said Mayor Bowser. “This DC Venture Capital Program is about investing in people, jobs, and the future of DC’s tech economy.”
The DC Venture Capital Fund represents a transformative commitment to DC-based businesses by leveraging public dollars to attract private investment. For every dollar the District invests, private investors are required to contribute at least an equal amount, effectively doubling the total funding available to DC startups to a minimum of $52 million.
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.–(BUSINESS WIRE)–United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced the world’s first transplant of a UKidney, which it produced, into a living person on November 25, 2024.
The transplant is the fourth xenotransplant using United Therapeutics’ xeno organs into living humans, following two successful UHeart transplants at the University of Maryland Medicine in 2022 and 2023 and a successful UThymoKidney transplant at NYU Langone Health earlier this year.
Guillermo Flor –
How to pitch to investors
The basics:
1. Venture Capitalists have an investment thesis they have to follow. If your startup doesn’t fit the investor’s thesis don’t bother pitching
2. Most times you’ll start pitching to associates. Then the associates will have to share the opportunity with the rest of their investment team. The easier you make their job the more chances you have.
3. How you pitch your startup gives out a lot of information about you to investors. Make sure your investment materials are organized, your pitch is concise and to the point and you are likeable.
GAITHERSBURG, Md., Dec. 16, 2024 (GLOBE NEWSWIRE) — Emergent BioSolutions Inc. (NYSE: EBS) today announced that the Biomedical Advanced Research and Development Authority (BARDA) within the Administration for Strategic Preparedness and Response (ASPR) at the U.S. Department of Health and Human Services has awarded a $50 million option to Emergent’s existing contract (HHSO100201600030C) for the acquisition of CYFENDUS® (Anthrax Vaccine Adsorbed, Adjuvanted).
By Ana Lucía Murillo – Staff Reporter, Washington Business Journal Connected DMV has tapped a new chief executive to lead the regionally focused nonprofit.
George Thomas, who has been with Connected DMV since its inception in 2019, is now president and CEO. The group’s founder and only CEO in its history, Stu Solomon, is now listed as executive chairman on the organization’s website. It’s unclear when the transition took place; Solomon was president and CEO as recently as May.
RICHMOND, VA, UNITED STATES, December 11, 2024 /EINPresswire.com/ — Liquet Medical Inc., a pioneering medical device company committed to advancing patient care through innovative technologies, today announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its Versus™ Catheter.
This innovative medical device is set to enhance the treatment of pulmonary artery blood clots by offering real-time pulmonary artery pressure measurements, empowering clinicians to optimize treatment based on individual patient responses. This novel technology enables a new treatment category called “Hemodynamics-Led Thrombolysis (HLT).”
GAITHERSBURG, Md., Dec. 13, 2024 /PRNewswire/ — Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced progress in Q4 2024 advancing its corporate growth strategy through its partnership with Sanofi. The Company has achieved a milestone associated with its Phase 2/3 clinical trial for its COVID-19 vaccine in children, triggering the first $50 million milestone payment from Sanofi.
WASHINGTON, Dec. 11, 2024 (GLOBE NEWSWIRE) — 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (60 Degrees Pharmaceuticals or the “Company”), a pharmaceutical company focused on developing new medicines for infectious diseases, announced today it has entered into a clinical trial agreement with Brigham and Women’s Hospital (BWH) in Boston to conduct a double-blind, placebo-controlled study evaluating the safety and efficacy of tafenoquine in combination with standard of care treatment for hospitalized babesiosis patients.
ANNAPOLIS, MD – Governor Wes Moore today announced that applications are being accepted for the Maryland Soft Landing Exchange Program, which allows Maryland companies to explore international markets at a reduced cost by connecting them with business incubators and accelerators abroad. The program, administered by the Maryland Department of Commerce, is designed to support companies who are ready to expand their existing export capabilities, and serves as an important enhancement to existing state export assistance.
Emmes®, part of Emmes Group®, a leading specialty tech and AI-enabled global contract research organization (CRO), today announced the appointment of Bryan Patterson to the newly created role of Senior Vice President, Government Business Development & Capture. This strategic expansion of Emmes’ leadership team underscores the company’s commitment to the U.S. Federal Government clinical research efforts, and to exceed expectations, drive innovation, and deliver even greater value.